INDICATIONS Retinal Vein Occlusion. OZURDEX ® (dexamethasone intravitreal implant) is indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Radiation Macular Edema after Ru106 Plaque Brachytherapy for Choroidal Melanoma Resolved by an Intravitreal Dexamethasone 0.7-mg Implant OZURDEX must be administered by a qualified ophthalmologist experienced in intravitreal injections. Posology. The recommended dose is one OZURDEX implant to be administered intra-vitreally to the affected eye. Indications and Usage Diabetic Macular Edema OZURDEX ® (dexamethasone intravitreal implant) is a corticosteroid indicated for the treatment of diabetic macular edema. To compare the efficacy of intravitreal injection of clindamycin and dexamethasone with classic treatment for ocular toxoplasmosis. Mohamed et al (2007) assessed the evidence for the effectiveness of interventions to improve visual acuity (VA) and prevent or treat neovascularization secondary to CRVO. Your responsibility. The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. Anti-inflammatory. Dexamethasone is used to treat many inflammatory and autoimmune conditions, such as rheumatoid arthritis and bronchospasm. Idiopathic thrombocytopenic purpura, a decrease in numbers of platelets due to an immune problem, responds to 40 mg daily for four days; it may be administered in 14-day cycles. FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE OZURDEX™ (dexamethasone intravitreal implant) is indicated for the treatment of macular edema following branch retinal vein The Scottish Medicines Consortium has advised (June 2012) that dexamethasone intravitreal implant (Ozurdex ®) is accepted for restricted use within NHS Scotland for the treatment of patients with macular oedema following central retinal vein occlusion, and in patients with branch retinal vein occlusion who are not clinically suitable for laser.